NCT03378219View on ClinicalTrials.gov

An Observational Study on Sarilumab-exposed Pregnancies

CompletedOBSERVATIONAL

Enrollment

113

Participants

Timeline

Start Date

May 18, 2018

Primary Completion Date

December 6, 2024

Study Completion Date

December 6, 2024

Conditions

Rheumatoid Arthritis -Exposure During Pregnancy

Interventions

DRUG

Sarilumab SAR153191 (REGN88)

Pharmaceutical form:injection Route of administration: subcutaneous

Trial Locations (2)

00000

United States, New York

Unknown

CANADA, Canada

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Sanofi

INDUSTRY